Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Operating income | -$136M | -$252M | -$263M | -$241M |
| Net income | -$131M | -$236M | -$244M | -$237M |
| EPS (diluted) | -$4.81 | -$3.63 | -$1.53 | -$1.45 |
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Operating cash flow | -$115M | -$163M | -$183M | -$206M |
| Capital expenditures | $511K | $117K | — | — |
| Free cash flow | -$115M | -$163M | — | — |
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Cash & equivalents | $241M | $374M | $142M | $183M |
| Total assets | $426M | $496M | $317M | $191M |
| Total liabilities | $29.4M | $27.1M | $29.9M | $87.2M |
| Long-term debt | — | — | — | $54.5M |
| Shareholders' equity | -$447M | $469M | $287M | $104M |
| Retained earnings | -$468M | -$703M | -$947M | -$1.18B |
| Shares (wtd avg diluted) | 27.2M | 65.0M | 159M | 163M |
Every figure is extracted from Neumora Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.